Providing a diverse range of perspectives from bullish to bearish, 23 analysts have published ratings on Travere Therapeutics TVTX in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 13 | 9 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 7 | 4 | 0 | 0 | 0 |
| 2M Ago | 5 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 3 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $21.96, a high estimate of $41.00, and a low estimate of $12.00. This current average reflects an increase of 18.57% from the previous average price target of $18.52.
Exploring Analyst Ratings: An In-Depth Overview
The analysis of recent analyst actions sheds light on the perception of Travere Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Greg Harrison | Scotiabank | Announces | Sector Outperform | $23.00 | - |
| Joseph Schwartz | Leerink Partners | Raises | Outperform | $40.00 | $20.00 |
| Greg Harrison | B of A Securities | Raises | Buy | $20.00 | $18.00 |
| Vamil Divan | Guggenheim | Raises | Buy | $41.00 | $23.00 |
| Laura Chico | Wedbush | Raises | Outperform | $25.00 | $17.00 |
| Joseph Schwartz | Leerink Partners | Maintains | Outperform | $20.00 | $20.00 |
| Carter Gould | Barclays | Raises | Overweight | $18.00 | $14.00 |
| Edward Nash | Canaccord Genuity | Lowers | Buy | $22.00 | $23.00 |
| Carly Kenselaar | Citigroup | Lowers | Buy | $19.00 | $23.00 |
| Vamil Divan | Guggenheim | Lowers | Buy | $23.00 | $25.00 |
| Greg Harrison | B of A Securities | Lowers | Buy | $18.00 | $19.00 |
| Ed Arce | HC Wainwright & Co. | Lowers | Buy | $18.00 | $23.00 |
| Anupam Rama | JP Morgan | Raises | Overweight | $23.00 | $20.00 |
| Edward Nash | Canaccord Genuity | Raises | Buy | $23.00 | $18.00 |
| Vamil Divan | Guggenheim | Announces | Buy | $25.00 | - |
| Carly Kenselaar | Citigroup | Raises | Buy | $23.00 | $14.00 |
| Greg Harrison | B of A Securities | Raises | Buy | $19.00 | $18.00 |
| Ed Arce | HC Wainwright & Co. | Raises | Buy | $23.00 | $20.00 |
| Anupam Rama | JP Morgan | Raises | Overweight | $20.00 | $19.00 |
| Ed Arce | HC Wainwright & Co. | Raises | Buy | $20.00 | $19.00 |
| Carter Gould | Barclays | Raises | Overweight | $14.00 | $12.00 |
| Allison Bratzel | Piper Sandler | Raises | Neutral | $12.00 | $11.00 |
| Laura Chico | Wedbush | Raises | Outperform | $16.00 | $13.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Travere Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Travere Therapeutics compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Travere Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.
Capture valuable insights into Travere Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Travere Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Travere Therapeutics's Background
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Travere Therapeutics's Financial Performance
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Travere Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 68.08%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Travere Therapeutics's net margin excels beyond industry benchmarks, reaching -130.11%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Travere Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -157.84%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -11.59%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 26.62, caution is advised due to increased financial risk.
What Are Analyst Ratings?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
